Trametinib improves progression-free survival among patients with low-grade serous ovarian carcinoma
1. The median progression-free survival for trametinib was significantly greater than that for...
Read MoreFeb 16, 2022
1. The median progression-free survival for trametinib was significantly greater than that for...
Read MoreFeb 15, 2022
1. Patients receiving pembrolizumab with or without platinum-based chemotherapy experienced longer...
Read MoreFeb 15, 2022
1. Overall, the influence of religion and spirituality on treatment decision making was both...
Read MoreFeb 15, 2022
1. In a large retrospective study, rates of venous thromboembolism (VTE) in pediatric patients...
Read MoreFeb 15, 2022
1. Overall survival is longer in patients treated with cemiplimab as compared to chemotherapy. 2....
Read More